TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04464694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Patients will receive single intravitreal injection of Ranibizumab 0.5 mg 3\~7 days before vitrectomy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Patients will receive single sham injection 3\~7 days before vitrectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy
Description: Surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pars plana vitrectomy
Description: Surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina
Study: NCT00918671

Intervention type: OTHER
Intervention: No new specific intervention
Description: No new specific intervention
Study: NCT00716183

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius HN6
Description: 9 log colony-forming units, capsules, daily, four weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri CR20
Description: 9 log colony-forming units, capsules, daily, four weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum LC40
Description: 9 log colony-forming units, capsules, daily, four weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-lactam antibiotic
Description: Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks (as prescribed by the physician responsible for the clinical diagnosis of lactational mastitis)
Study: NCT06303167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT00202137

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home blood pressure monitoring
Description: Monitor blood pressure using home blood pressure monitor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician monitoring of blood pressure
Description: Blood pressure measured as standard care from physician (no home monitor given for blood pressure monitoring)
Study: NCT06303167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologic Examination
Description: Undergo radiologic evaluation
Study: NCT01480856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cobedding
Description: Newborn twins are settled in a singe bed: this is cobedding

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Single-bedding
Description: Newborn twins are settled in two single beds : this is single-bedding
Study: NCT04373109

Intervention type: BEHAVIORAL
Intervention: Observation
Description: Observation of intensity of rehabilitation therapy, daily life upper limb use, physical activi-ty engagement, patient-reported quality of life, and motor outcome after stroke
Study: NCT03135379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated ultrasound gel
Description: Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) set to medium setting (102 degree fahrenheit).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Room temperature gel
Description: Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) turned off.
Study: NCT01842451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study: NCT03968432

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MIAS&Q
Description: There were two interventions compared in this study: 1) Be Sweet to Babies Videos and Pamphlet; and 2) Be Sweet to Babies Videos, pamphlet, and MIAS\&Q. The Be Sweet to Babies vaccination pain management videos and pamphlet were provided to all participants as this information is publicly available, and demonstrates the effectiveness of the evidence-based recommended vaccination pain management strategies for infants. In addition, a pamphlet was used which was developed in partnership with CHEO and Ottawa Public Health as a knowledge translation tool. Those in the intervention arm were also given MIAS\&Q included five questions and statements based on the MI approach consisted of four scaled questions and two open-ended questions, aimed to present brief informative and affirmative questions and statements to help the parents reflect on their own thoughts and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
Study: NCT02484417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV A2
Description: Intranasal inoculation of healthy volunteers with 10\^5 or 10\^6.3 plaque forming units (PFU) of RSV A2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV A2
Description: Intranasal inoculation of healthy volunteers with 10\^5 or 10\^6.3 plaque forming units (PFU) of RSV A2.
Study: NCT03968432

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Be Sweet to Babies Videos and Pamphlet
Description: The Be Sweet to Babies vaccination pain management videos and pamphlet will be provided to all participants. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of sweet solution during vaccination, will be used. This pamphlet is a knowledge translation tool previously developed in partnership with the Children Hospital of Eastern Ontario (CHEO) and Ottawa Public Health and has been publicly available on the Ottawa Public Health Website since June 2013. The content presented about pain management for infants during vaccination is the same information as the video.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Be Sweet to Babies Videos and Pamphlet
Description: The Be Sweet to Babies vaccination pain management videos and pamphlet will be provided to all participants. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of sweet solution during vaccination, will be used. This pamphlet is a knowledge translation tool previously developed in partnership with the Children Hospital of Eastern Ontario (CHEO) and Ottawa Public Health and has been publicly available on the Ottawa Public Health Website since June 2013. The content presented about pain management for infants during vaccination is the same information as the video.
Study: NCT04110522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct to patient PsA Screening Questionnaire
Description: Patients randomized to an intervention group will be asked to complete and score the 5-item Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Those patients with an elevated score (PEST ≥3 out of 5) will be advised to complete a rheumatologic evaluation for PsA.
Study: NCT02484417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV A2
Description: Intranasal inoculation of healthy volunteers with 10\^5 or 10\^6.3 plaque forming units (PFU) of RSV A2.
Study: NCT03999164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]DPA-714 Positron Emission Tomography Scan
Description: All patients will undergo a \[18F\]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
Study: NCT04091542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow/Ventilator
Description: Participants will have 2 days with optiflow, 2 days with ventilator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow/Ventilator
Description: Participants will have 2 days with optiflow, 2 days with ventilator.
Study: NCT02832206

Intervention type: PROCEDURE
Intervention: hybrid ablation
Description: Surgical thoracoscopic epicardial ablation (box-lesion) and left atrial appendage occlusion , followed (after 2-3months) by electrophysiological examination, and catheter ablation (completion of the box-lesion, cavotricuspid isthmus ablation and other ablation if indicated)
Study: NCT03372122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: A cloth to cleanse and disinfect the skin

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: HUBS with Hibiclens
Description: A dry cloth to be used in combination with water and antimicrobial soap to cleanse and disinfect the skin
Study: NCT04021303

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental cereal
Description: Cereal containing probiotics, prebiotic fiber and low carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cereal
Description: Gluten free conventional cereal (from 4 to 6 months old) and conventional cereal with gluten (from 7 to 12 months old)
Study: NCT03645759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I'm Whole
Description: I'm whole will provide 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education + usual care
Description: Will receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
Study: NCT02264522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Place dialysis chair into position 3.
Description: Upon device notification event 1, place patient in dialysis chair position 3.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease dialysate temperature.
Description: Upon device notification event 2, decrease dialysate temperature by 0.5 degree centigrade.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease ultrafiltration rate by 25%.
Description: Upon device notification event 3, decrease ultrafiltration rate by 25% from baseline ultrafiltration rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease ultrafiltration rate by 50%.
Description: Upon device notification event 4, decrease ultrafiltration rate by 50% from baseline ultrafiltration rate.
Study: NCT03126825

Intervention type: DEVICE
Group type: OTHER
Intervention: CP910/CP920 with noise reduction on
Description: This intervention uses the approved Nucleus 6 system (CP910/CP920 and accessories) but adds the investigational noise reduction algorithm.

Intervention type: DEVICE
Group type: OTHER
Intervention: CP910/CP920 with noise reduction on
Description: This intervention uses the approved Nucleus 6 system (CP910/CP920 and accessories) but adds the investigational noise reduction algorithm.

Intervention type: DEVICE
Group type: OTHER
Intervention: CP910/CP920
Description: The approved CP910 or CP920 Sound Processor.

Intervention type: DEVICE
Group type: OTHER
Intervention: CP910/CP920
Description: The approved CP910 or CP920 Sound Processor.
Study: NCT04470245

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: magnetic resonance imaging (MRI)
Description: Our study will include healthy volunteers (to refine the scanning sequence) and patients undergoing surgery for CTS. Patients will be scanned before and after their operation using cutting-edge diffusion MRI techniques.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: magnetic resonance imaging (MRI)
Description: Our study will include healthy volunteers (to refine the scanning sequence) and patients undergoing surgery for CTS. Patients will be scanned before and after their operation using cutting-edge diffusion MRI techniques.
Study: NCT01638325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC106 insulin lispro
Description: Administered SC
Study: NCT03994302

Intervention type: DRUG
Intervention: Drug inducing antiphospholipid syndrome
Description: Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome
Study: NCT04548063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6,000 word consent form
Description: Mock consent form with consistent content in approximately 6,000 word length.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4,000 word consent form
Description: Mock consent form with consistent content in approximately 4,000 word length.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2,000 word consent form
Description: Mock consent form with consistent content in approximately 2,000 word length.
Study: NCT01969110

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral IMPACT
Description: Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral IMPACT
Description: Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery
Study: NCT01665664

Intervention type: OTHER
Group type: OTHER
Intervention: Hypocaloric feeding
Description: Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
Study: NCT01024608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Description: Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Aerosol
Description: Placebo nasal aerosol administered each morning for two weeks.
Study: NCT03356639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6981
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6981
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6981
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6981
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT03794622

Intervention type: OTHER
Intervention: intramedullary nail fixation with bone marrow concentration
Description: intramedullary nail fixation with bone marrow concentration

Intervention type: OTHER
Intervention: intramedullary nail fixation
Description: intramedullary nail fixation only
Study: NCT03534973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine intake
Description: Cataract surgery in eyes with prior caffeine intake

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No caffeine intake
Description: Cataract surgery in eyes without prior caffeine intake
Study: NCT03251625

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Formula Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Formula Capsule
Study: NCT03114826

Intervention type: GENETIC
Intervention: To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker
Description: Study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker of the occurrence of renal cell carcinoma in renal transplant patients.
Study: NCT03775200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Dose-finding
Study: NCT03356639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study: NCT03775200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Dose-finding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Dose-finding
Study: NCT02969720

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phytosterols
Description: Oral daily consumption of 2 grams of phytosterols (8 ml) per 180 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Titanium Dioxide
Description: Oral daily consumption of Titanium Dioxide (8 ml) per 180 days.
Study: NCT03687567

Intervention type: PROCEDURE
Intervention: Preimplantation genetic diagnosis

Intervention type: PROCEDURE
Intervention: Preimplantation genetic diagnosis
Study: NCT01194570

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ocrelizumab
Description: Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two IV infusions of placebo matched to ocrelizumab in each treatment cycle of double blind treatment period.
Study: NCT03426384

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mymee Program
Description: A combination of digital therapeutics and telephonic health coaching is used to identify and test dietary, lifestyle, and environmental triggers in order to reduce symptoms of auto-immune disease.
Study: NCT02001194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual plus Team Incentives
Study: NCT00647283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gradual immunosuppression drug withdrawal
Description: After the obtention of biological samples (peripheral blood, liver tissue), enrolled patients undergo gradual weaning of all immunosuppressive therapy over a 6-9 month period under close medical supervision.
Study: NCT00168805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: 40 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: 150 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: 220 mg once daily
Study: NCT03185845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: tailored dose according to international normalized ratio (INR) for 3 months
Study: NCT04091542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow/Ventilator
Description: Participants will have 2 days with optiflow, 2 days with ventilator.
Study: NCT04197336

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric Embolization of Arteries with imaging visible Embolics
Description: The BEATLES study is an investigator-initiated, prospective, doubleblind, randomized, sham-controlled study that will assess the impact of bariatric embolization on the systemic levels of obesity related hormones and, as a consequence, on weight loss. The goal of this study is to help treat obesity combining a lifestyle program and a minimally invasive, angiographic (i.e., through blood vessels) approach.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Arm
Description: Participants randomized to the control arm will follow the same screening and pre-procedure assessment, and will also take the same pre-procedure medications. The procedural team instead will follow a prescribed simulated protocol that will mimic an actual embolization procedure.
Study: NCT04898764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate
Description: Mometasone furoate nasal spray suspension, 50µg/actuation
Study: NCT02777346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorbable
Description: Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non absorbable
Description: Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments.
Study: NCT04091542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow/Ventilator
Description: Participants will have 2 days with optiflow, 2 days with ventilator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow/Ventilator
Description: Participants will have 2 days with optiflow, 2 days with ventilator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow/Ventilator
Description: Participants will have 2 days with optiflow, 2 days with ventilator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow/Ventilator
Description: Participants will have 2 days with optiflow, 2 days with ventilator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow/Ventilator
Description: Participants will have 2 days with optiflow, 2 days with ventilator.